Soleno Therapeutics Inc. (SLNO)
68.23
-3.22 (-4.51%)
At close: Apr 01, 2025, 3:59 PM
68.23
0.00%
After-hours: Apr 01, 2025, 06:21 PM EDT
-4.51% (1D)
| Bid | 66.33 |
| Market Cap | 3.13B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -4.38 |
| PE Ratio (ttm) | -15.58 |
| Forward PE | -21.34 |
| Analyst | Strong Buy |
| Ask | 71 |
| Volume | 1,425,406 |
| Avg. Volume (20D) | 919,351 |
| Open | 70.11 |
| Previous Close | 71.45 |
| Day's Range | 66.51 - 71.29 |
| 52-Week Range | 36.61 - 73.97 |
| Beta | -1.69 |
About SLNO
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its n...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 13, 2014
Employees 92
Stock Exchange NASDAQ
Ticker Symbol SLNO
Website https://soleno.life
Analyst Forecast
According to 7 analyst ratings, the average rating for SLNO stock is "Strong Buy." The 12-month stock price forecast is $102, which is an increase of 49.49% from the latest price.
Stock Forecasts4 days ago
+6.83%
Soleno Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
6 days ago
+37.61%
Soleno Therapeutics shares are trading higher after the company announced it secured FDA approval for its first commercial drug for a rare genetic disorder.
